Posters presented at the 2025 American Academy of Dermatology Annual Meeting found bimekizumab to have benefits beyond safety ...

The BE RADIANT trial pitted bimekizumab against Novartis’ Cosentyx (secukinumab) in the treatment of adults with moderate-to-severe psoriasis, and according to UCB is the first study to compare ...

The first phase 3 data with UCB’s key pipeline drug bimekizumab show that it hit all its efficacy targets in psoriasis – and performed better than Johnson & Johnson’s blockbuster rival Stelara.

A novel drug almost entirely cleared moderate to severe psoriasis in over 60% of the patients who took part in two phase three clinical trials of a new drug. The University of Manchester and Salford ...

1-4 "A primary treatment goal for people living with psoriasis is durable, high rates of complete skin clearance. These five-year bimekizumab-bkzx results provide valuable evidence for clinical ...

Medscape News UK, February 20, 2025 Bimekizumab Shows Sustained Benefits in Psoriasis Bimekizumab was well tolerated and complete skin clearance was maintained over 3 years of treatment in ...

“Bimekizumab has had a remarkable launch, showing the excitement around IL-17A/F inhibition. We believe ORKA-002 could offer an even better product profile to people with psoriasis, psoriatic ...

These five-year bimekizumab-bkzx results provide valuable evidence for clinical decision-making," said Andrew Blauvelt, MD, MBA, Chair, Medical Board, National Psoriasis Foundation. "The sustained ...

These five-year bimekizumab-bkzx results provide valuable evidence for clinical decision-making," said Andrew Blauvelt, MD, MBA, Chair, Medical Board, National Psoriasis Foundation. "The sustained ...